

Index

- ACE: *see* Angiotensin-converting enzyme (ACE) inhibitors
- Acquired immunodeficiency syndrome (AIDS)
- extrapulmonary tuberculosis presentation in, 377
 - M. avium*-complex infections in patients with, 400–405
 - mycobacterial infections associated with, 401
 - prognosis and survival rates, 405
 - tuberculosis incidence/morbidity and, 372–373
- Adherent mononuclear cells, immunosuppression by, 247–251
- subpopulations responsible, 251–254
- Adjuvant moieties
- bacterial cell wall fraction, 40–41
 - cord factor, 40–41
 - MDP, 41–44
 - water-soluble adjuvant (WSA), 40–41
 - wax D, 40–41
- Adjuvanticity, genetic and gender control of, 43–44
- Affinity chromatography, as fractionation modality, 14–16
- AG: *see* A-Arabino-A-galactan (AG)
- AIDS: *see* Acquired immunodeficiency syndrome (AIDS)
- Alcoholics, tuberculosis among, 375–376
- α -antigen, isolation of, 16–17
- α -Interferon (IFN $_a$), in mycobacterial infections, 235
- Alveolar macrophages
- antimicrobial activity of, 305–306
 - BCG-immune resistance to phagosome destruction, 313–314
 - as first-line defense, 81–83
 - putative virulence factors of mycobacteria in, 316–322
 - T lymphocyte activation of, 85–86
- AM: *see* D-Arabino-D-mannan (AM)
- Anergy
- acquired, 187–193
 - immune suppression, dissemination and, 195–198
 - BCG-induced, 141
 - in experimental models, 186
 - to unrelated antigens, 220–223
 - in vitro* manifestations, 209–210
 - mechanisms, 210–217
 - in vivo*, manifestations, 217–220
 - innate specific, 193–198
 - overcoming by combined vaccination, 336
- Angiotensin-converting enzyme (ACE) inhibitors, for granulomatous inflammation control, 146
- Animal models, for BCG trials: *see* Rational animal models
- Anti-idiotypic antibody, in mycobacterial infections, 235
- Antibody
- immunoregulatory role in nonmycobacterial model systems, 264–265

Antibody (Cont.)

- levels compared, 25
- monoclonal, and antigen examination, 30
- in mycobacterial infections, 171–172
 - anti-idiotypic, 235
- polyclonal synthesis, MDP stimulated, 294–296
- to PPD, 91–92
- production, H-2 control of, 67–68

Antigens

- distribution classification, 7
- fractionation procedures, 10–12
 - survey, 12–21
- H-2 control of antibody production to, 67–68
- identification techniques for, 5–7
 - and immune system interactions, 86
- molecular biologic examination
 - approaches, 28–30
- presenting cells, for Ts-cell induction, 232
- unresponsiveness to: *see* Anergy
- variations in, 5

Antituberculosis drugs, *see also*

- individually named drugs
- action mode and dosage, 384–385
- adverse reactions to, 383–386
- effects of, 122–125

A-Arabino-A-galactan (AG),

- immunosuppressive effects of, 246–247

Aronson Trial, 348

- Ascaris suis*, granulomatous inflammation and, 139

B cells, polyclonal activation: *see*

- Polyclonal B-cell activator

B lymphocytes

- immunoregulatory role in
 - nonmycobacterial model systems, 264–265
- splenic, effect on granulomatous response, 270

Bacillary extracts, for tuberculin preparation, 4–7**Bacillus Calmette–Guérin (BCG)**

- and anergy *in vitro*
 - manifestations, 209–210
 - mechanisms, 210–217
- antigen identification and, 7

Bacillus Calmette–Guérin (BCG) (Cont.)

- CMI reactions to, regulatory
 - mechanisms in mice, 272–273
- DTH to, regulation in mice, 265–269
- field trials in humans: *see* BCG field trials
- granulomatous response to
 - inflammation induction, 140–142
 - regulation in mice, 270–271
- host resistance to, genetic control of, 142–143
- infection, genetic control of
 - in Biozzi mice, 61–62
 - intraspecies variation study, 61
 - in rabbits, 60
- M. bovis*
 - immune response to, 193–195
 - suppressor cells and, 227–228
- protective effect
 - in animal models, 353–355
 - Joint Field Trial–Laboratory Model Assay, 355
 - Rational Animal Model: *see* Rational animal models
 - in humans, factors determining, 350, 353; *see also* BCG field trials
 - environmental mycobacteria infection, 350–351
 - pathogenic path/cavitary pulmonary tuberculosis development, 352
 - tubercle bacilli virulence, 351–352
 - vaccine potency, 350
 - suppressor cell induction, 329–330
- Bacterial cell wall fraction, adjuvant activity of, 40–41
- BCG field trials, 347
 - Aronson—North American Indians, 348
 - British Medical Research Council, 348
 - Joint Field Trial–Laboratory Model Assay, 355
 - Tuberculosis Prevention—Chingleput District South India, 348–349
- Bcg* gene
 - genetics and phenotype expression, 62–63
 - immunologic consequences of, 67
- β -antigen, isolation of, 16
- Blastogenesis, regulation of, 247–249
- Bone marrow granulocyte-macrophage progenitor cells, MDP effect on, 45–46

- British Medical Research Council Trial, 348
- Bs lymphocytes, effect on granulomatous response, 270
- Candida albicans*, B lymphocyte/antibody immunoregulatory role in, 264–265
- Captopril, for granulomatous inflammation control, 146
- Carbon dioxide (CO₂), effect on tubercle bacilli uptake, 106
- Cavitary pulmonary tuberculosis
BCG protective effect in humans, factor determining, 352
hypothetical paths to, 343
tubercle bacilli in lungs, changes over time, 344–345
- Ceforanide, effects of, 125
- Cell–cell interactions, for Ts-cell induction
- Cell-mediated immunity (CMI), 83–84
B lymphocyte/antibody immunoregulatory role and, 264–265
leprosy and, 174–176
in mycobacterial infections, 171
reactions to BCG, regulatory mechanisms in mice, 272–273
- Cell-mediated suppressor mechanisms, in acquired anergy, 189–190
- Cell wall fraction, bacterial, adjuvant activity of, 40–41
- Cellular immunity, desensitization in, 50–51
- Central nervous system (CNS), effect of MDP on, 49–50
- Chemotherapy, basis of, 381; *see also* individually named drugs
- Children
M. scrofulaceum infection in, 392–393
tuberculosis among, 373
- Chingleput Tuberculosis Prevention Trial, 348–349
- Chromatography, as fractionation modality, 13–16; *see also* individually named modalities
- Cimetidine, for granulomatous inflammation control, 145–146
- Clones, CD8 T-cell, *M. tuberculosis*-reactive class I restriction of, 160, 161
establishment of, 158
IFN_γ secretion by, 158–159
- CNS: *see* Central nervous system (CNS)
- CO₂: *see* Carbon dioxide (CO₂)
- Compartmentalization, as mechanism of anergy, 181–182
- Con A: *see* Concanavalin A (Con A)
- Concanavalin A (Con A), T-cell activation and, 277
- Contact sensitivity model, 264–265, *see also* Oxazolone and Ts lymphocyte activation, 268–269
- Continuous-flow paper electrophoresis, as fractionation modality, 14
- Cord factor
adjuvant activity of, 40–41
in alveolar macrophages, 307, 317–320
phagosome destruction and, 315–316
structural formula of, 318
- Corticosteroids, in control of granulomatous inflammation, 143, 144–145
- CS: *see* Cycloserine (CS)
- Culture filtrates, for tuberculin preparation
heated, 3–4
unheated, 4
- Culture medium, influence on human macrophage uptake of tubercle bacilli, 104–105, 106
- Cyclooxygenase inhibitors, for granulomatous inflammation control, 144
- Cycloserine (CS)
side effects of, 385
in tuberculosis therapy, 379, 383
- Cyclosporin A, for granulomatous inflammation control, 143, 145
- Cytolytic cells
CD8 T-cell clones, *M. tuberculosis*-reactive, 160
mycobacterial growth inhibited by, 160, 162
CD8 T-cell lines, from *M. tuberculosis* immune mice, 154–158
- Delayed-type hypersensitivity (DTH), 39
anergy and
to unrelated antigens, 220–223
in vivo, 207, 217–220
to BCG, regulation in mice, 265–269
induction by WSA, 41
to PPD, 47
skin tests, depression of, 247–248

- Delayed-type hypersensitivity (DTH)
(*Cont.*)
 suppression, mycobacterial antigen-induced, 51–53
 suppressor cells and, 229–230
- Desensitization
 acquired anergy and, 187
 in cellular immunity, 50–51
- DNA molecular biologic methodology, for antigen examination, 29
- Donor serum, effect on intramacrophage growth of tubercle bacilli, 119–122
- DTH: *see* Delayed-type hypersensitivity (DTH)
- Effector cells, of suppression, 330–331
- Effector functions
 of mononuclear phagocytes, 244–245
 of T cells, 152–153
- Elderly, tuberculosis among, 374–375
- Electron microscopy, tubercle bacillus–human MP relationship morphology by, 129–130
- ELISA: *see* Enzyme-linked immunosorbent assay (ELISA)
- EMB: *see* Ethambutol (EMB)
- Enalapril, for granulomatous inflammation control, 146
- Environment
 and anergy, 184–186
 mycobacteria in, population sensitivity to, 350–351
- Enzyme-linked immunosorbent assay (ELISA), in tuberculosis diagnosis, 24–26
- Erdman tubercle bacilli
 generation times
 intracellular, 111–113
 intramacrophage, 113, 114
 growth rates in cultured MP, 110
- ETA: *see* Ethionamide (ETA)
- Ethambutol (EMB)
 effects of, 124–125
 side effects of, 385, 386
 in tuberculosis therapy, 378–383
- Ethionamide (ETA)
 side effects of, 385
 in tuberculosis therapy, 379, 383
- Extrapulmonary tuberculosis, in AIDS, 377
- Fogerty International Center (FIC), research objectives, 341
- Fractionation procedures, 10–12
 and immunoelectrophoresis, antigenic relationships between, 10–12
 modalities for, 13–16
 survey, 12–21
- γ -Interferon (IFN γ), MAF activity of, 245
- γ -irradiation, effect on adherant cell suppression, 253
- GDD: *see* Gel double-diffusion (GDD) procedure
- Gel double-diffusion (GDD) procedure, for tuberculosis diagnosis, 22
- Generation times, of Erdman tubercle bacilli
 intracellular, 111–113
 intramacrophage, 113, 114
- Genetic engineering, for antigen examination, 29–30
- Genetics
 and anergy, 184–186
 Bcg gene, 62–63
 and control of *M. tuberculosis*: *see under Mycobacterium tuberculosis*;
 Tuberculosis
 host resistance and, 73–74; *see also* Host resistance
 lymphokine production control by, 66–67
 and MDP adjuvanticity, 43–44
- Gold salt, for granulomatous inflammation control, 143, 145
- Granuloma formation
 immunogenetics of, 68
 MDP and, 44, 45
- Granulomatous inflammation
 defined, 137
 murine schistosomiasis as model of, 138–140
 pathologic roles, 138
 pharmacologic control of, 143–146
 as response to BCG, 140–142
 regulation in mice, 270–271
- Guinea pig model, for BCG protective effect studies, 360–364
 protein-deficient, 364–365
- H₂ receptor antagonists, for granulomatous inflammation control, 145–146

- Health care workers, tuberculosis among, 376
- HIV-I: *see* Human immunodeficiency virus (HIV-I)
- HLA: *see* Human leukocyte-antigen (HLA) complex
- Homeless, tuberculosis among, 375–376
- Host resistance, *see also*
 Immunocompromised host
 acquired, T-cell set and functions relevant to, 153–154
 after *M. lepraemurium* infection, 198
 to BCG, genetic control of, 142–143
 genetic control of, 73–74
 in Biozzi mice, 61–62
 intraspecies variation studies, 61
 inherited, in rabbits, 60
 MDP stimulation of, 46
- Human immunodeficiency virus (HIV-I), as AIDS cause, 400
- Human leukocyte-antigen (HLA) complex
 DR expression, on monocytes, 255–256
 restriction of immune responses, 70–71
 and tuberculosis, studies on, 71–73
- Human serum
 as factor in anergy, 183
 influence on human macrophage uptake of tubercle bacilli, 105, 107
- IFN: *see* Interferon (IFN)
- IL: *see* Interleukins (IL)
- Immigrants, tuberculosis among, 377
- Immune lymphokines, influence on macrophage uptake, 105
- Immune response
 adjuvant activities of MDP in, 42
 cellular, in leprosy patients, 333–335
 false-negative tuberculin reaction and, 172–173
 HLA restriction of, 70–71
 to *M. bovis* BCG, 193–195
 regulation in polyclonal lymphocyte activation, 283–285
 suppression by MDP, 46–49
 and virulence of tubercle bacilli, 82
- Immune suppression, acquired anergy, dissemination and, 195–198
- Immune system, and mycobacterial antigen interactions, 86
- Immunity: *see* Cell-mediated immunity (CMI); Cellular immunity; Tuberculoimmunity
- Immunoblotting, 27–28
- Immunocompetent cells, characteristics of, 93–95
- Immunocompromised host
M. avium-complex infections in, 397–400
 tuberculosis among, 375
- Immuno-electrophoresis
 antigen identification and, 6–7
 and tuberculin fractions, antigenic relationships between, 11–12
- Immunogenic moieties
 desensitization in cellular immunity, 50–51
 DTH suppression, antigen-induced, 51–53
 lymphokine production, 50
- Immunopathology, CD8 T cells role in, 165–167
- Immunoregulation
 antibody role in nonmycobacterial model systems, 264–265
 H-2 restriction in *M. tuberculosis* infection, 65–66
 in humans, 336
 in murine schistosomiasis, 139–140
 in tuberculosis and leprosy, 69–70
- Immunosuppression
 by adherant mononuclear cells, 247–251
 subpopulations responsible, 251–254
 anergy and, 178–179
 cellular properties associated with, 254–256
 mediators in tuberculosis, 256–259
 by mononuclear phagocytes, 245–246
- Immunosuppressive mycobacterial products, 246–247
- Indomethacin
 effect on AG suppression of PMNC responses to PPD, 246–247
 effect on T non- γ cell responses, 252
- INH: *see* Isoniazid (INH); Isonicotinic acid hydrazide (INH)
- Interferon (IFN)
 α , in mycobacterial infections, 235
 antiprotective effect of, 121–122
 γ
 MAF activity of, 245
 secretion by *M. tuberculosis*-reactive CD8 T-cell clones, 158–159
 and PPD responsiveness, 92–93

- Interferon (IFN) (*Cont.*)
 production following PPD stimulation, 90–91
 prostaglandins and, in mycobacterial infections, 235–236
- Interleukins (IL)
 IL-1
 and human tuberculosis lesion characteristics, 94–95
 PPD-induced, production by monocytes, 257–259
 and PPD responsiveness, 92–93
 IL-2
 effect on immune induction, 245
 and PPD responsiveness, 92–93
 production
 following PPD stimulation, 90–91
 regulation, 249–251
 suppressor cells and, in mycobacterial infections, 233–234
 production of, as mechanism of acquired energy, 190–193
- Ion-exchange chromatography, as fractionation modality, 13
- Irradiation
 γ , effect on adherant cell suppression, 253
 UV, effect on Ts-cell induction, 232–233
- Isoniazid (INH)
 effects of, 122, 125
 side effects of, 383, 384
 in tuberculosis therapy, 378–383
- Isonicotinic acid hydrazide (INH)
 effect on H37R_v toxicity for alveolar macrophages, 309
 effect on phagocyte destruction potential by H37R_v, 314–315
- Joint Field Trial-Laboratory Model Assay, 355
- Koch's Old tuberculin (OT)
 test, 2
 tuberculin preparation and, 3
 early studies, 7–8
- Latex beads, in phagosome destruction demonstration, 315–316
- Leprosy
 cellular immune response in, 333–335
 classification of, 174
- Leprosy (*Cont.*)
 immune defects and clinical status, 173–175
 immunoregulation in, 69–70
 mechanisms of immune disorders in, 175–178
 suppressor cells in, 230
 T suppressor cells' relationship to disease state, 335–336
- Lipids, from mycobacteria, 235
- Lipopolysaccharide (LPS)
 murine B cell activation, 277–278
 PPD-induced, production by monocytes, 257–259
- 5-lipoxygenase inhibitors, as inflammatory agents, 146
- Lymphocytes
 B, immunoregulatory role in nonmycobacterial model systems, 264–265
 Bs, effect on granulomatous response, 270
 polyclonal activation: *see* Polyclonal lymphocyte activation
 recirculation, as mechanism of acquired energy, 188–189
 T: *see* T lymphocytes
 Ts: *see* Ts lymphocytes
- Lymphokines
 antigen-generated, effect on tubercle bacilli uptake, 107
 immune, influence on human macrophage uptake of tubercle bacilli, 105, 107
 and PPD responsiveness, 92–93
 production of, 50
 genetic control in mycobacterial infections, 66–67
- Lysosome–phagosome fusion, virulent tubercle bacilli interference with, 310–311
- Macrophage activation factor (MAF), 245
- Macrophage migration inhibition factor (MIF)
 cellular immunity and, 50–51
 MDP and, 48–49
- Macrophages
 alveolar: *see* Alveolar macrophages
 uptake of tubercle bacilli: *see under* Tubercle bacilli
 virulent mycobacteria toxic to, 307–309

- MAF: *see* Macrophage activation factor (MAF)
- Major histocompatibility complex (MHC)
mycobacterial infections and, 66, 74
and T-cell types, 152
- MDP: *see* *N*-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP)
- MIF: *see* Macrophage migration inhibition factor (MIF)
- Mitogenicity, of MDP, 293–392
- Modulation, in murine schistosomiasis, 139
- Molecular exclusion chromatography, as fractionation modality, 14
- Monoclonal antibodies, and antigen examination, 30
- Monocytes
LPS- and PPD-induced IL-1 production by, 257
properties associated with
immunosuppression, 254–256
- Monocytic phagocytes (MP)
human, bacillary growth in, 110–111
antituberculosis drugs effect, 122–125
donor serum effect, 119–122
intracellular generation time differences, 115–119
intracellular variation, 111–113
original infection intensity effect, 113–114
strain virulence properties, 114–115
tubercle bacilli interaction with, 99–100
- Mononuclear cells, adherent,
immunosuppression by, 247–251
subpopulations responsible, 251–254
- Mononuclear phagocytes
immune induction and effector functions of, 244–245
immunosuppression by, 245–246
- Mouse models, for BCG protective effect studies, 357–359
- MP: *see* Monocytic phagocytes (MP)
- Muramyl dipeptide: *see* *N*-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP)
- Murine schistosomiasis, as model of granulomatous inflammation, 138–140
- Mycobacteria
atypical, suppressor cells and, 231
environmental, population sensitivity to, 350–351
- Mycobacteria (*Cont.*)
lipids from, 235
pathogenic: *see* Pathogenic mycobacteria
- Mycobacterial infections
AIDS associated, 401
antibody in, 171–172
anti-idiotypic, 235
cell-mediated immunity in, 171
lipids from mycobacteria in, 235
and major histocompatibility complex, 66, 74
phenolic glycolipid-I and Ts-cell induced activity in, 234
prostaglandins and interferons in, 235–236
suppressor cells and IL-2 in, 233–234
- Mycobacterium africanum*, evasion mechanisms of, 151
- Mycobacterium avium*
anergy and, 220–221
-complex infections
in AIDS patients, 400–405
in immunodepleted patients, 397–400
in normal population, 390–397
serotypes, 390, 394, 407–408
- Mycobacterium bovis*
BCG
immune response to, 193–195
suppressor cells and, 227–228
evasion mechanisms of, 151
growth inhibited by CD8 T cells, 160, 162
hyporesponsiveness in mice, 263–264
infection, suppressor cells in, 228–230
lymphocyte activation
from BCG-infected mice, 290–292
by whole cells and their fraction, 288–290
- Mycobacterium fortuitum* infection
in immunodepleted patients, 400
pulmonary tuberculosis and, 393
- Mycobacterium gordonae* infection, in immunodepleted patients, 400
- Mycobacterium intracellulare* infection,
virulence of, 390, 395–397
- Mycobacterium kansasii*
anergy and, 220–221
infection
in immunodepleted patients, 399–400
incidence and morbidity, 389–390
pulmonary tuberculosis and, 393

- Mycobacterium leprae*
infection with, 173–174
phenolic glycolipid-I as antigen specific to, 234
- Mycobacterium lepraemurium* infection
resistance of mice after, 198
suppressor cells in, 231
- Mycobacterium scrofulaceum* infection, in children, 392–393
- Mycobacterium simiae*
anergy and, 220–221
infection in immunodepleted patients, 400
- Mycobacterium smegmatis*, water-soluble fraction from, 296–297
- Mycobacterium tuberculosis*
adjuvant moieties role, 41–44
evasion mechanisms of, 151
genetic control
 Bcg gene, 62–63
 in Biozzi mice, 61–62
 of immunologic responses, 64–68
 inheritance mode analysis, 61
 intraspecies variation, 61
historical perspective, 1–3
immunogenic moieties role, 50–53
infection
 disseminated, acquired anergy and, 187–188
 experimental, anergy in, 186; *see also* Anergy
 H-2 control of antibody production, 67–68
 H-2 restriction of immunoregulatory events in, 65–66
 lymphokine production in, 66–67
 macrophage role, 81–83
 suppressor cells in, 228–230
molecular biologic approaches, 28–30
virulent H37r_v strain, phagosome destruction by, 311–313
 BCG-immune AM resistance to, 313–314
 effect of INH on potential for, 314–315
- Myelopoiesis, MDP effect and, 45–46
- N*-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP), 39–40, 292
adjuvant activity of, 41
 in immune response, 41
 target cells for, 42
- N*-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP) (*Cont.*)
adjuvanticity of, genetic and gender control of, 43–44
biologic activities of, 43
 bone marrow
 granulocyte/macrophage progenitor cells and, 45–46
 effect on CNS, 49–50
 granuloma formation, 44, 45
 host resistance stimulation, 46
 immune suppression, 46–49
 necrotic inflammatory reaction, 44–45
 mitogenicity of, 292–294
 polyclonal antibody synthesis stimulated by, 294–296
 suppressor cells and, 229
- Nafazatrom, for granulomatous inflammation control, 146
- Natural killer (NK) cells, adherent mononuclear cells and, 252–253
- NDGA: *see* Nordihydroguarietic acid (NDGA)
- Necrotic inflammatory reaction, MDP and, 44–45
- Niridazole, for granulomatous inflammation control, 143, 145
- NK: *see* Natural killer (NK) cells
- Nordihydroguarietic acid (NDGA), for granulomatous inflammation control, 146
- Ofloxacin, effects of, 124, 125
- Optical microscopy, tubercle bacillus–human MP relationship morphology by, 125–128
- OT: *see* Koch's Old tuberculin (OT)
- Oxazolone
 B lymphocyte/antibody immunoregulatory role and, 264–265
 and Ts lymphocyte activation, 268–269
- p*-aminosalicylic acid (PAS)
 side effects of, 385
 in tuberculosis therapy, 379
- PAGE: *see* Polyacrylamide gel electrophoresis (PAGE)
- PAS: *see* *p*-aminosalicylic acid (PAS)
- Pathogenic mycobacteria
 evasion mechanisms of, 151

- Pathogenic mycobacteria (*Cont.*)
 humoral defense mechanisms and, 151–152
- PBA: *see* Polyclonal B-cell activator (PBA)
- D-Penicillamine, for granulomatous inflammation control, 143, 145
- Peripheral mononuclear cells (PMNC)
 antigen-induced IL-2 production and blastogenesis in, 249–251
 proliferative response to PPD, 87–90
 responses to PPD, indomethacin effect on AG suppression of, 246–247
 suppressor cells and, 229
 in leprosy, 230
- PHA: *see* Phytohemagglutinin (PHA)
- Phagocytes
 monocytic: *see* Monocytic phagocytes (MP)
 mononuclear: *see* Mononuclear phagocytes
- Phagosome destruction, 311–313
 BCG-immune alveolar macrophage resistance to, 313–314
 demonstrated, 315–316
 effect of INH on, 314–315
- Phenotype expression, of Bcg gene, 62–63
- Physiochemical techniques, for antigen isolation, 16–18
- Phytohemagglutinin (PHA), polyclonal activation and, 277
- Pleurisy, tuberculous, 95
- PMNC: *see* Peripheral mononuclear cells (PMNC)
- Polyacrylamide gel electrophoresis (PAGE)
 as fractionation modality, survey, 19–21
 modified, 6–7
 mycobacterial antigen identification by, 5–6
- Polyclonal activation, 277
 of lymphocytes: *see* Polyclonal lymphocyte activation
- Polyclonal antibody synthesis, MDP stimulated, 294–296
- Polyclonal B-cell activator (PBA), 278
 tuberculin as, 278–279; *see also* Purified protein derivative (PPD)
- Polyclonal lymphocyte activation, 277–278
M. bovis and, 288–292
 muramyl dipeptides and, 292–296
 by tuberculin, 278–288
 WSA and, 296–297
- Preventative therapy, 386–387
- Primate models, for BCG protective effect studies, 357
- Prostaglandins
 E₂
 basal production by monocytes, 254
 as mediator in immunosuppression, 245–246
 and interferons, in mycobacterial infections, 235–236
- Pseudomonas aeruginosa*, B
 lymphocyte/antibody immunoregulatory role in, 264–265
- Pulmonary tuberculosis, *see also* Tuberculosis
 cavitory: *see* Cavitory pulmonary tuberculosis
 incidence
 in AIDS patients, 372–373
 in normal population, 393
 lesion characteristics, 93–94
- Purification, of adherent mononuclear cells, effect on T non- γ cell responses, 252
- Purified protein derivative (PPD)
 antibody to, 91–92
 and blastogenesis regulation, 247–249
 interleukin-2 production and, 90–91
 PMNC proliferative response to, 87–90
 as a polyclonal B-cell activator, 278–279
 B-cell subpopulation activation, 281–282
 genetic effects, 286–288
 of human lymphocytes, 285–286
 immune response regulation, 283–285
 mediator production, 282–283
 nonspecific effects
 lymphocyte activation, 279–281
 other, 288
 responsiveness, lymphokines and, 92–93
 standard (PPD-S), 4
 early studies, 9–12
 test, 2
 tuberculin preparation and, 3–4
 early studies, 8–9
- Pyrazinamide (PZA)
 effects of, 125
 side effects of, 383, 384
 in tuberculosis therapy, 378–383

- PZA: *see* Pyrazinamide (PZA)
- Radioimmunoassay (RIA), in tuberculosis diagnosis, 23–24
- Ranitidine, for granulomatous inflammation control, 145–146
- Rational animal models, BCG protective effect studies in guinea pig, 360–364
 - protein-deficient, 364–365
 - major variables constituting, 356
 - mouse, 357–359
 - primates, 357
 - selection, 356–357
- Resistance: *see* Host resistance
- RIA: *see* Radioimmunoassay (RIA)
- Rifampin (RIF)
 - as cause of thrombocytopenia, 383, 384
 - effects of, 123, 125
 - in tuberculosis therapy, 378–383
- SAFA: *see* Soluble antigen fluorescent antibody (SAFA) procedure
- Schistosoma mansoni*, granulomatous inflammation and, 137
- Segregation analysis, of inheritance mode of resistance to *M. tuberculosis*, 64
- Side effects, to antituberculosis drugs, 383–386
- Skin testing
 - false-negative reaction, causes of, 172–173
 - tuberculin preparation for
 - from bacillary extracts, 4–7
 - from culture filtrate
 - heated, 3–4
 - unheated, 4
 - early studies on, 7–12
 - other fractionation modalities, 12–21
- SM: *see* Streptomycin (SM)
- Soluble antigen fluorescent antibody (SAFA) procedure, for tuberculosis diagnosis, 22–23
- Staphylococcus aureus*, B
 - lymphocyte/antibody immunoregulatory role in, 264–265
- Streptococcus pneumoniae*, B
 - lymphocyte/antibody immunoregulatory role in, 264–265
- Streptomycin (SM)
 - effects of, 124
 - side effects of, 383, 384, 386
 - in tuberculosis therapy, 378–383
- Sulfatides, in alveolar macrophages, 320–321
- Sulfolipids, phagosome destruction and, 315–316
- Suppression, *see also* Immunosuppression
 - acquired anergy, dissemination and, 195–198
 - effector cells of, 330–331
 - mechanism of, 331–332
 - in anergy, 182–183
 - cell-mediated, in acquired anergy, 189–190
 - mediators of, 331
- Suppressor cells
 - in atypical mycobacteria and *M. leprae-murium* infection, 231
 - clinical observations of, 332–333
 - immunoregulation and, 336
 - in leprosy patients, 333–336
 - overcoming anergy, 336
 - experimental induction of, 327–329
 - effector cells and, 330–331
 - by killed BCG or its cell fractions, 329–330
 - mechanism for, 331–332
 - mediators, 331
 - and IL-2, in mycobacterial infections, 233–234
 - in leprosy, 230
 - in *M. bovis* and *M. tuberculosis* infection, 228–230
- Susceptibility: *see* Host resistance
- T cells
 - CD8
 - clones: *see* Clones
 - role in immunopathology, 165–167
 - role in tuberculosis, 162–164
 - as protection against, 164–165
 - CD4, role in tuberculosis, 164
 - with cytolytic activity from *M. tuberculosis* immune mice: *see* Cytolytic cells
 - effector functions of, 152–153
 - relevancy to acquired resistance against tuberculosis, 153–154

- T cells (*Cont.*)
 splenic: *see* Ts-cell induction; Ts lymphocytes
 suppressor type, and leprosy relationship, 335–336
 types, 152
- T lymphocytes, *see also* T cells
 activation of alveolar macrophages, 85–86
 CD8, and infected host cells interaction, 166–167
 and human tuberculosis lesion characteristics, 94
 splenic: *see* Ts lymphocytes
- T suppressor cells, and leprosy relationship, 335–336
- Target cells, for adjuvant activities of MDP, 43
- TCA: *see* Trichloroacetic acid (TCA)
- Thiacetazone (TZ)
 side effects of, 385
 in tuberculosis therapy, 379
- Toxicity, of virulent mycobacteria to macrophages, 307–309
- Trehalose dimycolate: *see* Cord factor
- Trichloroacetic acid (TCA), tuberculin preparation and, 3
 early studies, 9
- Ts-cell induction
 antigen-presenting cells for, 232
 phenolic glycolipid-I and, in mycobacterial infections, 234
 UV irradiation effect on, 232–233
- Ts lymphocytes
 activation by anti-Id B lymphocytes, 268–269
 effect on granulomatous response, 271
- Tube GDD test, for tuberculosis diagnosis, 22
- Tubercle bacilli
 animal models and data, 100
 Erdman: *see* Erdman tubercle bacilli
 human macrophage uptake of, 100–104
 culture medium influence, 104–105, 106
 human serum influence, 105, 107
 immune lymphokines influence, 105, 107
 quantitative characteristics, 101, 103
 variations, 107–110
- Tubercle bacilli (*Cont.*)
 killing of, 107–110
 factors involved, 82–83
 T-lymphocyte activation of alveolar macrophages, 85–86
 and monocytic phagocyte interaction, 99–100
 morphology of, 125–130
 system synopsis, 130–131
- virulent
 historical background, 305–307
 lysosome–phagosome fusion, interference with, 310–311
 phagosomal membrane disruption, 311–313
 toxicity to macrophages, 307–309
- Tuberculin, *see also* Purified protein derivative (PPD)
 false-negative reactions to, causes of, 172–173
 as polyclonal B-cell activator, 278–279
 preparation for skin testing, 3–7
 early studies, 7–12
 purified, 8
- Tuberculin skin test
 anergy *in vivo* and, 217–220
 history of, 2
- Tuberculoimmunity, human, *in vitro* model of, 86–92
- Tuberculosis
 in alcoholics, 375–376
 among immigrants, 377
 anergy, 178
 compartmentalization, 181–182
 genetic and environmental predispositions, 184–186
 serum factors, 183–184
 suppressor mechanisms, 182–183
 cavitary pulmonary: *see* Cavitary pulmonary tuberculosis
 cell-mediated immunity in, 83–84
 cellular focus of, 99–100
 in children, 373
 clinical presentation, 377–378
 diagnosis by serologic methods, 21–28
 epidemiology, 372
 extrapulmonary presentation in AIDS, 377
 genetic control of
Bcg gene, 62–63
 in Biozzi mice, 61–62

Tuberculosis (*Cont.*)

- genetic control of (*Cont.*)
 - in humans, 69–73; *see also* Human leukocyte-antigen (HLA) complex immunologic responses, 64–68
 - intraspecies variation studies, 61
 - resistance inheritance mode analysis, 64
 - in health care workers, 376
 - in homeless, 375–376
 - in immunocompromised hosts, 375
 - immunologic spectrum groups, 179–180
 - immunoregulation in, 69–70
 - incidence and morbidity, 372–373
 - inherited resistance in rabbits, 60
 - in old age, 374–375
 - pathogenesis of, key events, 342–347
 - T cells' role in
 - CD4, 164
 - CD8, 162–164
 - as protection against, 164–165
 - therapy for, 378–383; *see also*
 - Antituberculosis drugs;
 - Chemotherapy
 - preventative, 386–387
- Tuberculosis Prevention Trial (Chingleput District), 348–349
- Tuberculous lesions, bacterial populations in, 380
- Tuberculous pleurisy, 95
- TZ: *see* Thiacetazone (TZ)
- Unresponsiveness: *see* Anergy
- UV irradiation, effect on Ts-cell induction, 232–233

Vaccine

- BCG, protective effects of, 365–366; *see also* Bacillus Calmette–Guerin (BCG)

Vaccine (*Cont.*)

- combined, overcoming anergy by, 336
 - field trials: *see* BCG field trials
 - protective potency of, 350
 - WHO strategy, 59
- Virulence, *see also* Toxicity
- among strains of bacillus, 113–115
 - concept of, 306
 - expressed in normal alveolar macrophages, 316–317
 - cord factor, 317–320
 - other relevant mycobacterial components, 321–322
 - sulfatides, 320–321
 - as factor in immune response, 82
 - of *M. intracellulare*, 390, 395–397
 - of tubercle bacilli
 - historical background, 305–307
 - responsible for infection, 351–352
- 1,25(OH)₂Vitamin D₃, antituberculosis protectiveness of, 120, 121

Water-soluble adjuvant (WSA)

- activity of, 40–41
- from *M. smegmatis*, 296–297

Wax D

- adjuvant activity of, 40–41
- polyclonal lymphocyte activation and, 296–297

World Health Organization (WHO)

- BCG trial, 115
- fractionation method study, 21
- incidence estimates, 371
- tuberculosis immunology,
 - memorandum on, 95–96
- vaccine strategy, 59

WSA: *see* Water-soluble adjuvant (WSA)